A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)

Background: \- Inhibition of angiogenesis has demonstrable antitumor efficacy against castrate-resistant prostate cancer (CRPC). TRC105 is a human/murine chimeric immunoglobulin heavy constant gamma 1 (IgG1) kappa monoclonal antibody that binds to human CD105 (endoglin), thus inhibiting angiogenesis and tumor growth. Data from an ongoing phase I clinical trial suggest that TRC105 is well tolerated with evidence of clinical efficacy in patients with metastatic CRPC. Primary Objectives: \- Define the maximum tolerable dose (MTD) of TRC105 given every one to two weeks. Secondary Objectives: * Define the dose-limiting toxicities and toxicity profile of TRC105 given every one to two weeks * Evaluate time to disease progression, overall response rate and overall survival. * Describe the prostate specific antigen (PSA) response rate to therapy with TRC105 * Characterize the pharmacokinetics of TRC105 * Demonstrate a biologic effect of TRC105 in the patient and, when possible, on the tumor via laboratory evaluation of the molecular markers of angiogenesis before and after drug administration respectively Eligibility: * Progressive, castrate-resistant, metastatic adenocarcinoma of the prostate * Eastern Cooperative Oncology Group (ECOG) less than or equal to 2 Design: \- An initial single-arm, phase I dose escalation study open to all patients with progressive metastatic CRPC. The study will evaluate patients in five cohorts of escalating dose levels. A maximum of 30 patients will be needed to complete the phase I evaluation.